GlassScriptPhysician profile
Ronald J Rapoport
NPI 1336154764
$293,350.25
in general payments reported to CMS, 2019-2025
30 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $38K · 2021: $50K · 2022: $57K · 2023: $28K · 2024: $12K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $5,158 · Travel and Lodging: $2,364 · Consulting Fee: $1,810 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,912.50 |
| Food and Beverage | $5,158.02 |
| Travel and Lodging | $2,364.28 |
| Consulting Fee | $1,810.00 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $89,946.96 | 2019-2024 | Taltz |
| Amgen INC. | $82,076.99 | 2019-2025 | Evenity, Prolia, Enbrel |
| Glaxosmithkline, LLC. | $28,597.81 | 2019-2023 | Benlysta |
| Pfizer INC. | $26,089.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $24,103.94 | 2019-2025 | |
| Ucb, INC. | $11,255.88 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $9,561.94 | 2019-2025 | |
| Genzyme Corporation | $9,247.67 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $8,415.83 | 2019 | |
| Sobi, INC | $1,704.56 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $678.39 | 2022-2025 | Saphnelo |
| Pacira Pharmaceuticals Incorporated | $300.00 | 2024 | Exparel |
| Mallinckrodt Hospital Products INC. | $279.69 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $170.23 | 2019-2020 | |
| Janssen Biotech, INC. | $148.50 | 2019-2025 | Tremfya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $128.23 | 2019 | |
| Cardinal Health 110 LLC | $100.00 | 2025 | |
| Medexus Pharma, INC. | $93.20 | 2019-2020 | |
| Sandoz INC. | $89.18 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $75.57 | 2021 | |
| Alexion Pharmaceuticals, INC. | $70.45 | 2019-2021 | |
| Organon LLC | $59.12 | 2023-2024 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $33.72 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $21.76 | 2021 | |
| Aurinia Pharma U.S., INC. | $21.02 | 2021 | |
| Zyla Life Sciences, INC. | $19.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.82 | 2019 | |
| Pacira Therapeutics, INC. | $16.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.25 | 2019 | |
| Avion Pharmaceuticals | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Rapoport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.